Calcimedica reports 2023 financial results and provides clinical & corporate updates

Enrollment in carpo, phase 2b trial of auxora™ in acute pancreatitis (ap), on track with topline data expected in 2q 2024  auxora granted investigational new drug clearance by the fda for phase 2 trial in severe acute kidney injury (aki); kourage initiating in 2q 2024 crspa phase 1/2 trial of auxora in asparaginase-induced pancreatic toxicity (aipt) expanded and progressing to phase 2 following initial patient cohort results presented at ash 2023 following a private placement financing in january, company's cash position is expected to fund operations into 2h 2025 la jolla, calif. , march 28, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended december 31, 2023.
CALC Ratings Summary
CALC Quant Ranking